<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns="http://purl.org/rss/1.0/"
   xmlns:dc="http://purl.org/dc/elements/1.1/"
   xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
   xmlns:dcterms="http://purl.org/dc/terms/"

>
<channel rdf:about="http://www.citeulike.org/about">
<pubDate>Sat, 26 Jul 2008 04:18:59 BST</pubDate>


	<title>CiteULike: Author Isacson</title>
	<description>CiteULike: Author Isacson</description>


	<link>http://www.citeulike.org/author/Isacson</link>
	<dc:publisher>CiteULike.org</dc:publisher>
	<dc:language>en-gb</dc:language>
	<dc:rights>Copyright &#169; 2004-2008 citeulike.org</dc:rights>
	<items>
    <rdf:Seq>
        <rdf:li rdf:resource="http://www.citeulike.org/user/bhamcnil/article/228466"/>
        <rdf:li rdf:resource="http://www.citeulike.org/group/3378/article/2695534"/>
        <rdf:li rdf:resource="http://www.citeulike.org/user/thenose/article/2158221"/>
        <rdf:li rdf:resource="http://www.citeulike.org/user/hplatero/article/771852"/>
        <rdf:li rdf:resource="http://www.citeulike.org/user/jclau/article/1558748"/>
        <rdf:li rdf:resource="http://www.citeulike.org/user/stevezhang/article/1533975"/>
        <rdf:li rdf:resource="http://www.citeulike.org/user/sonichedgehog/article/972841"/>
        <rdf:li rdf:resource="http://www.citeulike.org/user/jeremymiller/article/942319"/>
        <rdf:li rdf:resource="http://www.citeulike.org/user/brian/article/346518"/>
        <rdf:li rdf:resource="http://www.citeulike.org/user/brian/article/346516"/>

	</rdf:Seq>
	</items>
	</channel>


<item rdf:about="http://www.citeulike.org/user/bhamcnil/article/228466">
    <title>Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.</title>
    <link>http://www.citeulike.org/user/bhamcnil/article/228466</link>
    <description>&lt;i&gt;J Neurosci, Vol. 24, No. 43. (27 October 2004), pp. 9553-9560.&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;Dopamine (DA) receptors play a central role in such diverse pathologies as Parkinson's disease, schizophrenia, and drug abuse. We used an amphetamine challenge combined with pharmacologic magnetic resonance imaging (phMRI) to map DA-associated circuitry in nonhuman primates with high sensitivity and spatial resolution. Seven control cynomolgous monkeys and 10 MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-treated parkinsonian primates were studied longitudinally using both positron emission tomography (PET) and phMRI. Amphetamine challenge (2.5 mg/kg, i.v.) in control monkeys increased relative cerebral blood volume (rCBV) in a number of brain regions not described previously, such as parafascicular thalamus, precentral gyrus, and dentate nucleus of the cerebellum. With the high spatial resolution, we were also able to readily identify changes in rCBV in the anterior cingulate, substantia nigra, ventral tegmental area, caudate (tail and head), putamen, and nucleus accumbens. Amphetamine induced decreases in rCBV in occipital and posterior parietal cortices. Parkinsonian primates had a prominent loss of response to amphetamine, with relative sparing of the nucleus accumbens and parafascicular thalamus. There was a significant correlation between rCBV loss in the substantia nigra and both PET imaging of dopamine transporters and behavioral measures. Monkeys with partial lesions as defined by 2beta-carbomethoxy-3beta-(4-fluorophenyl) tropane binding to dopamine transporters showed recruitment of premotor and motor cortex after amphetamine stimulus similar to what has been noted in Parkinson's patients during motor tasks. These data indicate that phMRI is a powerful tool for assessment of dynamic changes associated with normal and dysfunctional DA brain circuitry in primates.</description>
    <dc:title>Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.</dc:title>

    <dc:creator>BG Jenkins</dc:creator>
    <dc:creator>R Sanchez-Pernaute</dc:creator>
    <dc:creator>AL Brownell</dc:creator>
    <dc:creator>YC Chen</dc:creator>
    <dc:creator>O Isacson</dc:creator>
    <dc:identifier>doi:10.1523/JNEUROSCI.1558-04.2004</dc:identifier>
    <dc:source>J Neurosci, Vol. 24, No. 43. (27 October 2004), pp. 9553-9560.</dc:source>
    <dc:date>2005-06-15T14:09:51-00:00</dc:date>
    <prism:publicationYear>2004</prism:publicationYear>
    <prism:publicationName>J Neurosci</prism:publicationName>
    <prism:issn>1529-2401</prism:issn>
    <prism:volume>24</prism:volume>
    <prism:number>43</prism:number>
    <prism:startingPage>9553</prism:startingPage>
    <prism:endingPage>9560</prism:endingPage>
    <prism:category>no-tag</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/group/3378/article/2695534">
    <title>Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease</title>
    <link>http://www.citeulike.org/group/3378/article/2695534</link>
    <description>&lt;i&gt;Proceedings of the National Academy of Sciences, Vol. 105, No. 15. (15 April 2008), pp. 5856-5861.&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;The long-term goal of nuclear transfer or alternative reprogramming approaches is to create patient-specific donor cells for transplantation therapy, avoiding immunorejection, a major complication in current transplantation medicine. It was recently shown that the four transcription factors Oct4, Sox2, Klf4, and c-Myc induce pluripotency in mouse fibroblasts. However, the therapeutic potential of induced pluripotent stem (iPS) cells for neural cell replacement strategies remained unexplored. Here, we show that iPS cells can be efficiently differentiated into neural precursor cells, giving rise to neuronal and glial cell types in culture. Upon transplantation into the fetal mouse brain, the cells migrate into various brain regions and differentiate into glia and neurons, including glutamatergic, GABAergic, and catecholaminergic subtypes. Electrophysiological recordings and morphological analysis demonstrated that the grafted neurons had mature neuronal activity and were functionally integrated in the host brain. Furthermore, iPS cells were induced to differentiate into dopamine neurons of midbrain character and were able to improve behavior in a rat model of Parkinson's disease upon transplantation into the adult brain. We minimized the risk of tumor formation from the grafted cells by separating contaminating pluripotent cells and committed neural cells using fluorescence-activated cell sorting. Our results demonstrate the therapeutic potential of directly reprogrammed fibroblasts for neuronal cell replacement in the animal model. 10.1073/pnas.0801677105</description>
    <dc:title>Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease</dc:title>

    <dc:creator>Marius Wernig</dc:creator>
    <dc:creator>Jian-Ping Zhao</dc:creator>
    <dc:creator>Jan Pruszak</dc:creator>
    <dc:creator>Eva Hedlund</dc:creator>
    <dc:creator>Dongdong Fu</dc:creator>
    <dc:creator>Frank Soldner</dc:creator>
    <dc:creator>Vania Broccoli</dc:creator>
    <dc:creator>Martha Constantine-Paton</dc:creator>
    <dc:creator>Ole Isacson</dc:creator>
    <dc:creator>Rudolf Jaenisch</dc:creator>
    <dc:identifier>doi:10.1073/pnas.0801677105</dc:identifier>
    <dc:source>Proceedings of the National Academy of Sciences, Vol. 105, No. 15. (15 April 2008), pp. 5856-5861.</dc:source>
    <dc:date>2008-04-21T09:52:23-00:00</dc:date>
    <prism:publicationYear>2008</prism:publicationYear>
    <prism:publicationName>Proceedings of the National Academy of Sciences</prism:publicationName>
    <prism:volume>105</prism:volume>
    <prism:number>15</prism:number>
    <prism:startingPage>5856</prism:startingPage>
    <prism:endingPage>5861</prism:endingPage>
    <prism:category>stemcells</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/user/thenose/article/2158221">
    <title>Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons</title>
    <link>http://www.citeulike.org/user/thenose/article/2158221</link>
    <description>&lt;i&gt;Journal of Neurochemistry, Vol. 104, No. 2. (January 2008), pp. 316-324.&lt;/i&gt;</description>
    <dc:title>Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons</dc:title>

    <dc:creator>Hong</dc:creator>
    <dc:creator>Sunghoi</dc:creator>
    <dc:creator>Kang</dc:creator>
    <dc:creator>Un Jung</dc:creator>
    <dc:creator>Isacson</dc:creator>
    <dc:creator>Ole</dc:creator>
    <dc:creator>Kim</dc:creator>
    <dc:creator>Kwang-Soo</dc:creator>
    <dc:identifier>doi:10.1111/j.1471-4159.2007.04952.x</dc:identifier>
    <dc:source>Journal of Neurochemistry, Vol. 104, No. 2. (January 2008), pp. 316-324.</dc:source>
    <dc:date>2007-12-22T03:07:17-00:00</dc:date>
    <prism:publicationYear>2008</prism:publicationYear>
    <prism:publicationName>Journal of Neurochemistry</prism:publicationName>
    <prism:issn>0022-3042</prism:issn>
    <prism:volume>104</prism:volume>
    <prism:number>2</prism:number>
    <prism:startingPage>316</prism:startingPage>
    <prism:endingPage>324</prism:endingPage>
    <prism:publisher>Blackwell Publishing</prism:publisher>
    <prism:category>no-tag</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/user/hplatero/article/771852">
    <title>Specific microRNAs modulate embryonic stem cell-derived neurogenesis.</title>
    <link>http://www.citeulike.org/user/hplatero/article/771852</link>
    <description>&lt;i&gt;Stem Cells, Vol. 24, No. 4. (April 2006), pp. 857-864.&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;MicroRNAs (miRNAs) are recently discovered small non-coding transcripts with a broad spectrum of functions described mostly in invertebrates. As post-transcriptional regulators of gene expression, miRNAs trigger target mRNA degradation or translational repression. Although hundreds of miRNAs have been cloned from a variety of mammalian tissues and cells and multiple mRNA targets have been predicted, little is known about their functions. So far, a role of miRNA has only been described in hematopoietic, adipocytic, and muscle differentiation; regulation of insulin secretion; and potentially regulation of cancer growth. Here, we describe miRNA expression profiling in mouse embryonic stem (ES) cell- derived neurogenesis in vitro and show that a number of miRNAs are simultaneously co-induced during differentiation of neural progenitor cells to neurons and astrocytes. There was a clear correlation between miRNA expression profiles in ES cell-derived neurogenesis in vitro and in embryonal neurogenesis in vivo. Using both gain-of-function and loss-of-function approaches, we demonstrate that brain-specific miR-124a and miR-9 molecules affect neural lineage differentiation in the ES cell-derived cultures. In addition, we provide evidence that signal transducer and activator of transcription (STAT) 3, a member of the STAT family pathway, is involved in the function of these miRNAs. We conclude that distinct miRNAs play a functional role in the determination of neural fates in ES cell differentiation.</description>
    <dc:title>Specific microRNAs modulate embryonic stem cell-derived neurogenesis.</dc:title>

    <dc:creator>AM Krichevsky</dc:creator>
    <dc:creator>KC Sonntag</dc:creator>
    <dc:creator>O Isacson</dc:creator>
    <dc:creator>KS Kosik</dc:creator>
    <dc:identifier>doi:10.1634/stemcells.2005-0441</dc:identifier>
    <dc:source>Stem Cells, Vol. 24, No. 4. (April 2006), pp. 857-864.</dc:source>
    <dc:date>2006-07-25T03:34:01-00:00</dc:date>
    <prism:publicationYear>2006</prism:publicationYear>
    <prism:publicationName>Stem Cells</prism:publicationName>
    <prism:issn>1066-5099</prism:issn>
    <prism:volume>24</prism:volume>
    <prism:number>4</prism:number>
    <prism:startingPage>857</prism:startingPage>
    <prism:endingPage>864</prism:endingPage>
    <prism:category>quiescence</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/user/jclau/article/1558748">
    <title>Histopathological and Clinical Criteria for Analyzing Transplanted Human Dopamine Cells in Parkinson’s Disease</title>
    <link>http://www.citeulike.org/user/jclau/article/1558748</link>
    <description>&lt;i&gt;Restorative Therapies in Parkinson’s Disease (2006), pp. 166-183.&lt;/i&gt;</description>
    <dc:title>Histopathological and Clinical Criteria for Analyzing Transplanted Human Dopamine Cells in Parkinson’s Disease</dc:title>

    <dc:creator>Ole Isacson</dc:creator>
    <dc:creator>Nicholas Lange</dc:creator>
    <dc:creator>Oliver Cooper</dc:creator>
    <dc:creator>Rosario Sanchez-Pernaute</dc:creator>
    <dc:identifier>doi:10.1007/0-387-32823-8_9</dc:identifier>
    <dc:source>Restorative Therapies in Parkinson’s Disease (2006), pp. 166-183.</dc:source>
    <dc:date>2007-08-13T19:56:20-00:00</dc:date>
    <prism:publicationYear>2006</prism:publicationYear>
    <prism:publicationName>Restorative Therapies in Parkinson’s Disease</prism:publicationName>
    <prism:startingPage>166</prism:startingPage>
    <prism:endingPage>183</prism:endingPage>
    <prism:category>clinical</prism:category>
    <prism:category>dopamine</prism:category>
    <prism:category>geostatistics</prism:category>
    <prism:category>histology</prism:category>
    <prism:category>immunohistochemistry</prism:category>
    <prism:category>kriging</prism:category>
    <prism:category>mixed-effects</prism:category>
    <prism:category>parkinsons</prism:category>
    <prism:category>pd</prism:category>
    <prism:category>post-mortem</prism:category>
    <prism:category>statistics</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/user/stevezhang/article/1533975">
    <title>Temporally induced Nurr1 can induce a non-neuronal dopaminergic cell type in embryonic stem cell differentiation.</title>
    <link>http://www.citeulike.org/user/stevezhang/article/1533975</link>
    <description>&lt;i&gt;Eur J Neurosci, Vol. 19, No. 5. (March 2004), pp. 1141-1152.&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;The nuclear transcription factor Nurr1 is involved in the development and maintenance of the midbrain dopaminergic (DA) neuronal phenotype. We analysed the cellular and biological effects of Nurr1 during embryonic stem (ES) cell differentiation using the ROSA26-engineered Tet-inducible ES cell line J1-rtTA that does not express transgenes in mature neurons. Induction of Nurr1 at nestin-positive precursor and later stages of ES cell differentiation produced a non-neuronal DA cell type including functional DA transporters. In these cells, we found a clear correlation between Nurr1 and TH gene expression and specific midbrain DA cellular markers such as AADC, AHD2 and calbindin. Nurr1 did not alter gene expression of non-DA neuronal phenotypes and did not influence other midbrain developmental transcription factors, such as Otx1, Otx2, En-1, GBX2, Pitx3 and lmx1b. In addition, Nurr1 expression was required for maintenance of the DA phenotype and mediated up-regulation of the tyrosine kinase Ret and associated trophic factor GDNF-family receptors alpha 1, 2, and 4. This demonstrates that Nurr1 is sufficient to induce and maintain a midbrain-like DA biochemical and functional cellular phenotype independent of neurogenesis.</description>
    <dc:title>Temporally induced Nurr1 can induce a non-neuronal dopaminergic cell type in embryonic stem cell differentiation.</dc:title>

    <dc:creator>KC Sonntag</dc:creator>
    <dc:creator>R Simantov</dc:creator>
    <dc:creator>KS Kim</dc:creator>
    <dc:creator>O Isacson</dc:creator>
    <dc:identifier>doi:10.1111/j.1460-9568.2004.03204.x</dc:identifier>
    <dc:source>Eur J Neurosci, Vol. 19, No. 5. (March 2004), pp. 1141-1152.</dc:source>
    <dc:date>2007-08-03T23:07:54-00:00</dc:date>
    <prism:publicationYear>2004</prism:publicationYear>
    <prism:publicationName>Eur J Neurosci</prism:publicationName>
    <prism:issn>0953-816X</prism:issn>
    <prism:volume>19</prism:volume>
    <prism:number>5</prism:number>
    <prism:startingPage>1141</prism:startingPage>
    <prism:endingPage>1152</prism:endingPage>
    <prism:category>gdnf</prism:category>
    <prism:category>nurr1</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/user/sonichedgehog/article/972841">
    <title>Enhanced Yield of Neuroepithelial Precursors and Midbrain-Like Dopaminergic Neurons from Human Embryonic Stem Cells Using the BMP Antagonist Noggin.</title>
    <link>http://www.citeulike.org/user/sonichedgehog/article/972841</link>
    <description>&lt;i&gt;Stem Cells (12 October 2006)&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;It is currently not known whether dopamine (DA) neurons derived from human embryonic stem cells (hESCs) can survive in vivo and alleviate symptoms in models of Parkinson's disease (PD). Here, we report the use of Noggin (a bone-morphogenic protein antagonist) to induce neuroectodermal cell development and increase the yield of DA neurons from hESCs. A combination of stromal-derived inducing activity (SDIA) and Noggin markedly enhanced the generation of neuroepithelial progenitors that could give rise to DA neurons. In addition, Noggin diminished the occurrence of a fibroblast-like Nestin-positive precursor population that differentiated into myocytes. After transplantation of differentiated hESCs to a rodent model PD, some grafts contained human midbrain-like DA neurons. This protocol demonstrates hESC derivation and survival of hDA neurons appropriate for cell therapy in PD.</description>
    <dc:title>Enhanced Yield of Neuroepithelial Precursors and Midbrain-Like Dopaminergic Neurons from Human Embryonic Stem Cells Using the BMP Antagonist Noggin.</dc:title>

    <dc:creator>Kai-Christian Sonntag</dc:creator>
    <dc:creator>Jan Pruszak</dc:creator>
    <dc:creator>Takahito Yoshizaki</dc:creator>
    <dc:creator>Joris van Arensbergen</dc:creator>
    <dc:creator>Rosario Sanchez-Pernaute</dc:creator>
    <dc:creator>Ole Isacson</dc:creator>
    <dc:identifier>doi:10.1634/stemcells.2006-0380</dc:identifier>
    <dc:source>Stem Cells (12 October 2006)</dc:source>
    <dc:date>2006-12-04T05:45:03-00:00</dc:date>
    <prism:publicationYear>2006</prism:publicationYear>
    <prism:publicationName>Stem Cells</prism:publicationName>
    <prism:issn>1066-5099</prism:issn>
    <prism:category>noggin</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/user/jeremymiller/article/942319">
    <title>Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.</title>
    <link>http://www.citeulike.org/user/jeremymiller/article/942319</link>
    <description>&lt;i&gt;Hum Mol Genet, Vol. 14, No. 13. (1 July 2005), pp. 1709-1725.&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;Molecular differences between dopamine (DA) neurons may explain why the mesostriatal DA neurons in the A9 region preferentially degenerate in Parkinson's disease (PD) and toxic models, whereas the adjacent A10 region mesolimbic and mesocortical DA neurons are relatively spared. To characterize innate physiological differences between A9 and A10 DA neurons, we determined gene expression profiles in these neurons in the adult mouse by laser capture microdissection, microarray analysis and real-time PCR. We found 42 genes relatively elevated in A9 DA neurons, whereas 61 genes were elevated in A10 DA neurons [&#62; 2-fold; false discovery rate (FDR) &#60; 1%]. Genes of interest for further functional analysis were selected by criteria of (i) fold differences in gene expression, (ii) real-time PCR validation and (iii) potential roles in neurotoxic or protective biochemical pathways. Three A9-elevated molecules [G-protein coupled inwardly rectifying K channel 2 (GIRK2), adenine nucleotide translocator 2 (ANT-2) and the growth factor IGF-1] and three A10-elevated peptides (GRP, CGRP and PACAP) were further examined in both alpha-synuclein overexpressing PC12 (PC12-alphaSyn) cells and rat primary ventral mesencephalic (VM) cultures exposed to MPP+ neurotoxicity. GIRK2-positive DA neurons were more vulnerable to MPP+ toxicity and overexpression of GIRK2 increased the vulnerability of PC12-alphaSyn cells to the toxin. Blocking of ANT decreased vulnerability to MPP+ in both cell culture systems. Exposing cells to IGF-1, GRP and PACAP decreased vulnerability of both cell types to MPP+, whereas CGRP protected PC12-alphaSyn cells but not primary VM DA neurons. These results indicate that certain differentially expressed molecules in A9 and A10 DA neurons may play key roles in their relative vulnerability to toxins and PD.</description>
    <dc:title>Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.</dc:title>

    <dc:creator>CY Chung</dc:creator>
    <dc:creator>H Seo</dc:creator>
    <dc:creator>KC Sonntag</dc:creator>
    <dc:creator>A Brooks</dc:creator>
    <dc:creator>L Lin</dc:creator>
    <dc:creator>O Isacson</dc:creator>
    <dc:source>Hum Mol Genet, Vol. 14, No. 13. (1 July 2005), pp. 1709-1725.</dc:source>
    <dc:date>2006-11-14T01:26:50-00:00</dc:date>
    <prism:publicationYear>2005</prism:publicationYear>
    <prism:publicationName>Hum Mol Genet</prism:publicationName>
    <prism:issn>0964-6906</prism:issn>
    <prism:volume>14</prism:volume>
    <prism:number>13</prism:number>
    <prism:startingPage>1709</prism:startingPage>
    <prism:endingPage>1725</prism:endingPage>
    <prism:category>lcm</prism:category>
    <prism:category>parkinsons</prism:category>
    <prism:category>single_cell</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/user/brian/article/346518">
    <title>Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data.</title>
    <link>http://www.citeulike.org/user/brian/article/346518</link>
    <description>&lt;i&gt;Magn Reson Med, Vol. 38, No. 3. (September 1997), pp. 389-398.&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;The metabolic activation resulting from direct dopaminergic stimulation can be detected using auto-radiography, positron emission tomography (PET) or, potentially, fMRI techniques. To establish the validity of the latter possibility, we have performed a number of experiments. We measured the regional selectivity of two different dopaminergic ligands: the dopamine release compound D-amphetamine and the dopamine transporter antagonist 2 beta-carbomethoxy-3 beta-(4-fluoropheny) tropane (CFT). Both compounds led to increased signal intensity in gradient echo images in regions of the brain with high dopamine receptor density (frontal cortex, striatum, cingulate cortex &#62; &#62; parietal cortex). Lesioning the animals with unilaterally administered 6-hydroxydopamine (6-OHDA) led to ablation of the phMRI response on the ipsilateral side; control measurements of rCBV and rCBF using bolus injections of Gd-DTPA showed that the baseline rCBV and rCBF values were intact on the lesioned side. The time course of the BOLD signal changes paralleled the changes observed by microdialysis measurements of dopamine release in the striatum for both amphetamine and CFT; peaking at 20-40 min after injection and returning to baseline at about 70-90 min. Signal changes were not correlated with either heart rate, blood pressure or pCO2. Measurement of PET binding in the same animals showed an excellent correlation with the phMRI data when compared by either measurements of the number of pixels activated or percent signal change in a given region. The time course for the behavioral measurements of rotation in the 6-OHDA lesioned animals correlated with the phMRI. These experiments demonstrate that phMRI will become a valuable, noninvasive tool for investigation of neurotransmitter activity in vivo.</description>
    <dc:title>Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data.</dc:title>

    <dc:creator>YC Chen</dc:creator>
    <dc:creator>WR Galpern</dc:creator>
    <dc:creator>AL Brownell</dc:creator>
    <dc:creator>RT Matthews</dc:creator>
    <dc:creator>M Bogdanov</dc:creator>
    <dc:creator>O Isacson</dc:creator>
    <dc:creator>JR Keltner</dc:creator>
    <dc:creator>MF Beal</dc:creator>
    <dc:creator>BR Rosen</dc:creator>
    <dc:creator>BG Jenkins</dc:creator>
    <dc:source>Magn Reson Med, Vol. 38, No. 3. (September 1997), pp. 389-398.</dc:source>
    <dc:date>2005-10-10T01:04:06-00:00</dc:date>
    <prism:publicationYear>1997</prism:publicationYear>
    <prism:publicationName>Magn Reson Med</prism:publicationName>
    <prism:issn>0740-3194</prism:issn>
    <prism:volume>38</prism:volume>
    <prism:number>3</prism:number>
    <prism:startingPage>389</prism:startingPage>
    <prism:endingPage>398</prism:endingPage>
    <prism:category>no-tag</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/user/brian/article/346516">
    <title>Insights into Parkinson's disease models and neurotoxicity using non-invasive imaging.</title>
    <link>http://www.citeulike.org/user/brian/article/346516</link>
    <description>&lt;i&gt;Toxicol Appl Pharmacol, Vol. 207, No. 2 Suppl. (1 September 2005), pp. 251-256.&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;Loss of dopamine in the nigrostriatal system causes a severe impairment in motor function in patients with Parkinson's disease and in experimental neurotoxic models of the disease. We have used non-invasive imaging techniques such as positron emission tomography (PET) and functional magnetic resonance imaging (MRI) to investigate in vivo the changes in the dopamine system in neurotoxic models of Parkinson's disease. In addition to classic neurotransmitter studies, in these models, it is also possible to characterize associated and perhaps pathogenic factors, such as the contribution of microglia activation and inflammatory responses to neuronal damage. Functional imaging techniques are instrumental to our understanding and modeling of disease mechanisms, which should in turn lead to development of new therapies for Parkinson's disease and other neurodegenerative disorders.</description>
    <dc:title>Insights into Parkinson's disease models and neurotoxicity using non-invasive imaging.</dc:title>

    <dc:creator>R Sánchez-Pernaute</dc:creator>
    <dc:creator>AL Brownell</dc:creator>
    <dc:creator>BG Jenkins</dc:creator>
    <dc:creator>O Isacson</dc:creator>
    <dc:identifier>doi:10.1016/j.taap.2005.02.039</dc:identifier>
    <dc:source>Toxicol Appl Pharmacol, Vol. 207, No. 2 Suppl. (1 September 2005), pp. 251-256.</dc:source>
    <dc:date>2005-10-10T00:55:36-00:00</dc:date>
    <prism:publicationYear>2005</prism:publicationYear>
    <prism:publicationName>Toxicol Appl Pharmacol</prism:publicationName>
    <prism:issn>0041-008X</prism:issn>
    <prism:volume>207</prism:volume>
    <prism:number>2 Suppl</prism:number>
    <prism:startingPage>251</prism:startingPage>
    <prism:endingPage>256</prism:endingPage>
    <prism:category>dopamine</prism:category>
    <prism:category>fmri</prism:category>
    <prism:category>imaging</prism:category>
    <prism:category>parkinsons</prism:category>
    <prism:category>pet</prism:category>
</item>



</rdf:RDF>

